We recently published an article titled These 10 Companies Led Monday’s Downturn. In this article, we are going to take a ...

Viking Therapeutics VKTX has outperformed the market over the past 5 years by 22.07% on an annualized basis producing an ...

Two healthcare stocks in the white-hot weight-loss segment tanked on Monday as one of their rivals zoomed higher. The ...

Viking Therapeutics got the market's attention with robust phase 2 results for VK2735, a potential weight loss therapy.

B. Riley lowered the firm’s price target on Viking Therapeutics (VKTX) to $96 from $109 and keeps a Buy rating on the shares.

Viking Therapeutics is a clinical-stage biotech company focused on developing weight-loss therapies. Read why I rate VKTX ...

Shares of Viking Therapeutics have fallen by more than half since the stock peaked early last year. Viking Therapeutics is developing a drug that might be able to outperform today's most popular ...

The excitement surrounding Viking Therapeutics (NASDAQ: VKTX) stock has been dying down significantly lately. Many investors ...

Maxim lowered the firm’s price target on Viking Therapeutics (VKTX) to $70 from $120 and keeps a Buy rating on the shares after the company’s ...

Market uncertainty makes investors nervous about investing in speculative industries. But Wall Street has high hopes for ...

Citi analyst David Lebowitz initiated coverage of Viking Therapeutics (VKTX) with a Neutral rating and $38 price target Viking’s VK2735 is an ...

When the market closed on Feb. 5, shares of Viking Therapeutics were down about 65% from the peak they reached in 2024. Is Viking Therapeutics stock a bargain at its beaten-down price?